Table 3.
Characteristics of the JGCA-IN and JGCA-OUT cohorts before and after propensity score matching (PSM)
| Before PSM | After PSM | |||||
|---|---|---|---|---|---|---|
| JGCA-IN (n = 209) |
JGCA-OUT (n = 70) |
P | JGCA-IN (n = 105) |
JGCA-OUT (n = 70) |
p | |
| Age (years) | 65 (11.9) | 65 (12.6) | 0.960 | 64 (12.3) | 65 (12.6) | 0.637 |
| Sex | ||||||
|
Female Male |
100 (47.9%) 109 (52.1%) |
26 (37.1%) 44 (62.9%) |
0.129 |
46 (43.8%) 59 (56.2%) |
26 (37.1%) 44 (62.9%) |
0.380 |
| BMI | 24.7 (4.5) | 24.9 (3.8) | 0.610 | 24.5 (4.3) | 24.9 (3.8) | 0.497 |
| ASA classification | ||||||
|
1 2 3 |
21 (10%) 162 (77.5%) 26 (12.5%) |
9 (13%) 53 (76.8%) 6 (8.7%) |
0.717 |
13 (12.4%) 78 (74.3%) 14 (13.3%) |
9 (13%) 53 (76.8%) 6 (8.7%) |
0.503 |
| cT stage | ||||||
|
T1 T2 T3 T4 |
30 (14.3%) 94 (45%) 72 (34.5%) 13 (6.2%) |
2 (2.9%) 25 (35.7%) 35 (50%) 8 (11.4%) |
0.006 |
7 (6.7%) 33 (31.4%) 53 (50.5%) 12 (11.4%) |
2 (2.9%) 25 (35.7%) 35 (50%) 8 (11.4%) |
0.701 |
| cN stage | ||||||
|
N0 N+ |
129 (61.7%) 80 (38.3%) |
30 (42.9%) 40 (57.1%) |
0.006 |
53 (50.5%) 52 (49.5%) |
30 (42.9%) 40 (57.1%) |
0.323 |
| Preoperative stage | ||||||
|
I IIA IIB III |
95 (45.4%) 29 (13.9%) 34 (16.3%) 51 (24.4%) |
16 (22.9%) 11 (15.7%) 14 (20%) 29 (41.4%) |
0.006 |
29 (27.6%) 11 (10.5%) 24 (22.9%) 41 (39.5%) |
16 (22.9%) 11 (15.7%) 14 (20%) 29 (41.4%) |
0.681 |
| CEA | ||||||
|
< 5 ng/ml > 5 ng/ml |
163 (78%) 20 (22%) |
45 (80.4%) 11 (19.6%) |
0.089 |
80 (87%) 12 (13%) |
45 (80.4%) 11 (19.6%) |
0.282 |
| Preoperative histology | ||||||
|
Intestinal Diffuse |
130 (62.2%) 79 (37.8%) |
41 (58.6%) 29 (41.4%) |
0.589 |
53 (50.5%) 52 (49.5%) |
41 (58.6%) 29 (41.4%) |
0.293 |
| Neoadjuvant chemotherapy |
171 (81.8%) 38 (18.2%) |
45 (64.3%) 25 (35.7%) |
0.005 |
77 (73.3%) 28 (26.7%) |
45 (64.3%) 25 (35.7%) |
0.202 |
| Gastrectomy extent | ||||||
|
Distal Total |
176 (84.2%) 33 (15.8%) |
44 (62.9%) 26 (37.1%) |
< 0.0001 |
77 (73.3%) 28 (26.7%) |
44 (62.9%) 26 (37.1%) |
0.142 |
| Lymphadenectomy extent | ||||||
|
D1 D2 |
29 (13.9%) 180 (85.1%) |
10 (14.3%) 60 (85.7%) |
0.932 |
11 (10.5%) 94 (90.5%) |
10 (14.3%) 60 (85.7%) |
0.247 |
| PRM (cm) | 6 (2–16) | 2.5 (0.5–4) | < 0.0001 | 5.5 (2–16) | 2.5 (0.5–4) | < 0.001 |
| DRM (cm) | 4 (0.2–21) | 4 (0.5–25) | 0.276 | 4 (0.2–19) | 4 (0.5–25) | 0.100 |
| Lymph node sampling adequacy | ||||||
|
Adequate Inadequate |
191 (91.4%) 18 (8.6%) |
65 (92.9%) 5 (7.1%) |
0.699 |
97 (92.4%) 8 (7.6%) |
65 (92.9%) 5 (7.1%) |
0.906 |
| pN stage | ||||||
|
pN0 pN+ |
98 (47%) 111 (53%) |
16 (23%) 54 (77%) |
0.0004 |
23 (22%) 82 (78%) |
16 (23%) 54 (77%) |
0.999 |
p values < 0.05 are indicated in bold
Data are presented as number (percentage), mean (standard deviation), or median (range), as appropriate. BMI body mass index, ASA American Society of Anesthesiologists, cT,N,M clinical T, N, M stage, CEA carcinoembryonic antigen, PRM proximal resection margin, DRM distal resection margin